Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
Background Mature tertiary lymphoid structures have been reported to play a major role in the efficacy of PD-L1 blockade in non-small cell lung cancer. In TLS-positive NSCLC, the objective response rate to single-agent PD1/PD-L1 inhibition is similar to response rates observed in all-comer NSCLC patients treated with immune checkpoint inhibitors combined with chemotherapy. However, a […]
Indoleamine 2,3-dioxygenase 1 is expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
Background Immune checkpoint inhibitors have revolutionized the management of patients with non-small cell lung cancer. However, most patients with advanced NSCLC display primary resistance to these treatments. Indoleamine 2,3-dioxygenase 1, or IDO1, may contribute to immune regulation by catabolizing tryptophan into several immunosuppressive metabolites, including kynurenine. This study aimed to investigate the role of IDO1 […]
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy
Background Most cancer patients treated with anti-PD1 or anti-PDL1 immune checkpoint blockers do not derive clinical benefit. There is therefore a crucial need to identify reliable predictive biomarkers of response. Beyond PD1, several immune checkpoints, including CTLA4, LAG3, TIM3 and TIGIT, are associated with a T cell exhausted phenotype and play an important role in […]
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Functional evidence for an immunosuppressive role of kynurenine in cancer patients
Background Long neglected, tumor immune escape is now considered a key mechanism promoting tumor growth and immune evasion. Beyond the prototypical PD1/PDL1 axis, several additional pathways have been identified as important contributors to the immune editing process. Indoleamine 2,3-dioxygenase 1, or IDO1, is a first rate-limiting enzyme of the kynurenine pathway. This pathway has been […]